Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: Molecular mechanisms unveiled by gene expression profiling

Biochemical Pharmacology

Volumn 85, Issue 8, 2013, Pages 1077-1090

  Koch, Martin ^a   Krieger, Michaela L ^a   Stölting, Daniel ^a   Brenner, Norbert ^b   Beier, Manfred ^c   Jaehde, Ulrich ^a   Wiese, Michael ^a   Royer, Hans Dieter ^b,c   Bendas, Gerd ^a  

^a UNIVERSITY OF BONN   (Germany)

^b CENTER OF ADVANCED EUROPEAN STUDIES AND RESEARCH CAESAR   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Apoptosis; CDDP resistance; Gene expression profiling; Liposomal CDDP; Ovarian cancer

Indexed keywords

CASPASE 9; CISPLATIN; PROTEIN BAX; PROTEIN BID; SIRTUIN 1; SIRTUIN 2; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL ADHESION; CONCENTRATION RESPONSE; DNA DAMAGE; DNA REPLICATION; DRUG CYTOTOXICITY; ENDOPLASMIC RETICULUM; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE LOCATION; HUMAN; HUMAN CELL; IC 50; LIPOSOMAL DELIVERY; MITOSIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; HYDROXAMIC ACIDS; LIPOSOMES; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84875222709     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.01.028     Document Type: Article

References (50)

1. Y. Jung, and S.J. Lippard Direct cellular responses to platinum-induced DNA damage Chemical Rev 2006 107
2. S.N. Powell, and R.S. Bindra Targeting the DNA damage response for cancer therapy DNA Repair (Amst) 8 2009 1153 1165
3. X-J. Liang, S. Mukherjee, D-W. Shen, F.R. Maxfield, and M.M. Gottesman Endocytic recycling compartments altered in cisplatin-resistant cancer cells Cancer Res 66 2006 2346 2353
4. D.W. Shen, Pouliot.F L.M., M.D. Hall, and M.M. Gottesman Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes Pharmacol Rev 64 2012 706 721
5. S.P.C. Cole, and R.G. Deeley Transport of glutathione and glutathione conjugates by MRP1 Trends Pharmacol Sci 27 2006 438 446
6. M. Pasello, F. Michelacci, I. Scionti, C.M. Hattinger, M. Zuntini, and A.M. Caccuri Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma Cancer Res 68 2008 6661 6668
7. G. Francia, S.K. Green, G. Bocci, S. Man, U. Emmenegger, and J.M.L. Ebos Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents Mol Cancer Ther 4 2005 1484 1494
8. M. Yin, J. Yan, E. Martinez-Balibrea, F. Graziano, H-J. Lenz, and H-J. Kim ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis Clin Cancer Res 17 2011 1632 1640
9. J.Q. Cheng, X. Jiang, M. Fraser, M. Li, H.C. Dan, and M. Sun Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway Drug Resist Update 5 2002 131 146
10. B.C. Behrens, T.C. Hamilton, H. Masuda, K.R. Grotzinger, J. Whang-Peng, and K.G. Louie Characterization of a c/s-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues Cancer Res 47 1987 414 418
11. M.L. Krieger, N. Eckstein, V. Schneider, M. Koch, H-D. Royer, and U. Jaehde Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro Int J Pharm 389 2010 10 17
12. G.P. Stathopoulos, D. Antoniou, J. Dimitroulis, J. Stathopoulos, K. Marosis, and P. Michalopoulou Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer Cancer Chemother Pharmacol 68 2011 945 950
13. G. Bendas, A. Krause, U. Bakowsky, J. Vogel, and U. Rothe Targetability of novel immunoliposomes prepared by a new antibody conjugation technique Int J Pharm 181 1999 79 93
14. M. Muscolini, R. Cianfrocca, A. Sajeva, S. Mozzetti, G. Ferrandina, and A. Costanzo Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells Mol Cancer Ther 7 2008 1410 1419
15. E. Brouwers, M. Tibben, H. Rosing, J. Schellens, and J. Beijnen The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research Mass Spectrom Rev 2008 67 100 10.1002/mas.20159
16. G.K. Smyth Linear models and empirical bayes methods for assessing differential expression in microarray experiments Stat Appl Genet Mol Biol 3 2004 Article3
17. M. Koch, H-D. Royer, and M. Wiese A microarray tool provides pathway and GO term analysis Mol Inf 30 2011 918 921
18. D.W. Huang, B.T. Sherman, Q. Tan, J.R. Collins, W.G. Alvord, and J. Roayaei The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists Genome Biol 8 2007 R183
19. D. Nishimura BioCarta Biotech Software Internet Rep 2 2001 117 120
20. M. Kanehisa, and S. Goto KEGG: kyoto encyclopedia of genes and genomes Nucleic Acids Res 28 2000 27 30
21. P. Shannon, A. Markiel, O. Ozier, N.S. Baliga, J.T. Wang, and D. Ramage Cytoscape: a software environment for integrated models of biomolecular interaction networks Genome Res 13 2003 2498 2504
22. A.A. Lane, and B.A. Chabner Histone deacetylase inhibitors in cancer therapy J Clin Oncol 27 2009 5459 5468
23. J.S. Carew, F.J. Giles, and S.T. Nawrocki Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy Cancer Lett 269 2008 7 17
24. S.M. Sancho-Martinez, L. Prieto-Garcia, M. Prieto, J.M. Lopez-Novoa, and F.J. Lopez-Hernandez Subcellular targets of cisplatin cytotoxicity: an integrated view Pharmacol Ther 136 2012 35 55
25. X.J. Liang, T. Finkel, D.W. Shen, J.J. Yin, A. Aszalos, and M.M. Gottesman SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism Mol Cancer Res 6 2008 1499 1506
26. J. Yuan, K. Luo, T. Liu, and Z. Lou Regulation of SIRT1 activity by genotoxic stress Genes Dev 26 2012 791 796
27. N.M. Martins, N.A. Santos, C. Curti, M.L. Bianchi, and A.C. Santos Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver J Appl Toxicol 28 2008 337 344
28. H. Alborzinia, S. Can, P. Holenya, C. Scholl, E. Lederer, and I. Kitanovic Real-time monitoring of cisplatin-induced cell death PloS ONE 6 2011 e19714
29. S.J. Lippard, and J.D. Hoeschele Binding of cis- and trans- dichlorodiammineplatinum(II) to the nucleosome core Proc Natl Acad Sci USA 76 1979 6091 6095
30. H. Vakifahmetoglu, M. Olsson, and B. Zhivotovsky Death through a tragedy: mitotic catastrophe Cell Death Differ 15 2008 1153 1162
31. R. Brown, C. Clugston, P. Burns, A. Edlin, P. Vasey, and B. Vojtsek Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 1993 678 684
32. P. Bragado, A. Armesilla, A. Silva, and A. Porras Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation Apoptosis 12 2007 1733 1742
33. I. Dolado, A. Swat, N. Ajenjo, G. De Vita, and A. Cuadrado Nebreda AR. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis Cancer Cell 11 2007 191 205
34. H. Maeda, G.Y. Bharate, and J. Daruwalla Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur J Pharm Biopharm 71 2009 409 419
35. M.E. Davis, Z.G. Cheng, and D.M. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat Rev Drug Discov 7 2008 771 782
36. U.S. Huth, R. Schubert, and R. Peschka-Suss Investigating the uptake and intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-imaging J Control Release 110 2006 490 504
37. I.H. Hamelers, R.W. Staffhorst, J. Voortman, B. de Kruijff, J. Reedijk, and P.M. van Bergen en Henegouwen High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis Clin Cancer Res 15 2009 1259 1268
38. H. Masuda, R.F. Ozols, G. Lai, A. Fojo, M. Rothenberg, and T.C. Hamilton Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines Cancer Res 48 1988 5713 5716
39. P. Solar, and A.J. Sytkowski Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780 Cancer Lett 309 2011 11 18
40. J.W. Kim, H. Sahm, J. You, and M. Wang Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells Anticancer Res 30 2010 2577 2581
41. S. Aggarwal, T. He, W. Fitzhugh, K. Rosenthal, B. Feild, and J. Heidbrink Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer Gynecologic Oncol 115 2009 430 437
42. N.P. Chappell, P.N. Teng, B.L. Hood, G. Wang, K.M. Darcy, and C.A. Hamilton Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer J Proteome Res 11 2012 4605 4614
43. C. Settembre, R. Zoncu, D.L. Medina, F. Vetrini, S. Erdin, and T. Huynh A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB EMBO J 31 2012 1095 1108
44. D. Wang, and S.J. Lippard Cellular processing of platinum anticancer drugs Nat Rev Drug Discov 4 2005 307 320
45. D.G. Deavall, E.A. Martin, J.M. Horner, and R. Roberts Drug-induced oxidative stress and toxicity J Toxicol 2012 2012 645460
46. A.M. Rahman, S.W. Yusuf, and M.S. Ewer Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation Int J Nanomed 2 2007 567 583
47. S.E. Winograd-Katz, and A. Levitzki Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor Oncogene 25 2006 7381 7390
48. G.S. Wu, T.F. Burns, E.R. McDonald, W. Jiang, R. Meng, and I.D. Krantz KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene Nat Genet 17 1997 141 143
49. Zhan Q. Gadd 45a, a p53- and BRCA1-regulated stress protein, in cellular response to DNA damage Mutat Res 569 2005 133 143
50. M. Schuijer, and E.M. Berns TP53 and ovarian cancer Hum Mutat 21 2003 285 291